Margaret Lanahan Grapperhaus

This inventor holds 42 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 1 EPO patent, primarily in Cholesterol Inhibitors. Top assignees: Pharmacia Corporation, G.d. Searle & Company, Pfizer Corporation. Active years: 2001-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Margaret Lanahan Grapperhaus. Retrieved from https://idiyas.com/inventor/margaret-lanahan-grapperhaus

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 42 (Patent Applications = 5)

% Patents Active = 9.5

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 15.3

ph-index = 8

Forward Citations = 300(Granted Patents)

Company Filing History:

19 out of 220

Pharmacia Corporation

patents

12 out of 1,323

G.d. Searle & Company

Pharmacia Corporation Global Patent Department

patent

Years Active: 2001-2020

Loading Chart...

Areas of Expertise:

Cholesterol Ester Transfer Protein

Bruton's Tyrosine Kinase

Aminoalcohol Compounds

Nitric Oxide Synthase

Pyrazole Derivatives

Protease Inhibitors

Chiral Halogenated Compounds

Fused Heterocyclic Amino Compounds

Cycloalkyl Aminoalcohols

Non-Fused Heterocyclo Amino Compounds

Disubstituted Amino Compounds

Phenyl Aminoalcohol Compounds

42 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10815213 - Bruton's tyrosine kinase inhibitors (2020-10-27),

2. 10266513 - Bruton's tyrosine kinase inhibitors (2019-04-23),

3. 8097733 - Pyrazole derivatives as 5-LO-inhibitors (2012-01-17),

4. 7700658 - (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity (2010-04-20),

5. 7253211 - (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity (2007-08-07),

6. 7122536 - (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity (2006-10-17),

7. 7119203 - Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors (2006-10-10),

8. 6951889 - 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors (2005-10-04),

9. 6803388 - (R)-Chiral halogenated substituted n,n-bis-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-10-12),

10. 6787570 - Substituted N-cycloalkyl-N-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-09-07),

11. 6765023 - Use of substituted N, N-disubstituted reverse aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-07-20),

12. 6723753 - Substituted n-benzyl-n-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-04-20),

13. 6723752 - (R)-chiral halogenated substituted n-benzyl-n-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-04-20),

14. 6710089 - Substituted N-fused-phenyl-N-benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-03-23),

15. 6699898 - Substituted N,N-disubstituted non-fused heterocyclo amino compounds useful for inhibiting cholesteryl ester transfer protein activity (2004-03-02),

Title: The Visionary Inventor: Margaret Lanahan Grapperhaus

Introduction

Margaret Lanahan Grapperhaus, a visionary inventor hailing from Troy, IL (US), stands as a shining example of passion and dedication in the world of innovation. With an impressive portfolio of 42 patents to her name, Grapperhaus continues to inspire generations of inventors and shape the future of technology.

Latest Patents

Among her latest patents is the groundbreaking work on Bruton's tyrosine kinase inhibitors. These compounds, which establish covalent bonds with BTK, offer promising avenues for treating autoimmune diseases, cancer (including lymphoma), and inflammatory conditions. The methods for preparing these compounds, as well as their inclusion in pharmaceutical compositions, underscore Grapperhaus's innovative prowess in the field.

Career Highlights

Grapperhaus has made significant contributions to companies such as Pharmacia Corporation and G.D. Searle & Company, where her inventive spirit and expertise have driven advancements in pharmaceuticals and healthcare. Her tireless dedication to research and development has led to transformative solutions that benefit society at large.

Collaborations

Throughout her career, Grapperhaus has collaborated with esteemed colleagues such as James A. Sikorski and Lijuan Jane Wang. These partnerships have fostered a culture of innovation, leading to the successful realization of novel ideas and the patenting of groundbreaking technologies.

Conclusion

In conclusion, Margaret Lanahan Grapperhaus's remarkable journey as an inventor exemplifies the power of ingenuity and perseverance in driving positive change. Her innovative approach to addressing complex challenges has not only left a lasting impact on the field of technology but also serves as an inspiration for future inventors seeking to push the boundaries of what is possible.

Profile summary based on public USPTO records.